Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IntroSpect Digital Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"atai Life Sciences and Introspect Digital Therapeutics to Test Novel Digital Therapeutic Approach in Patients Receiving Ketamine","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by IntroSpect Digital Therapeutics

    Menu

    IntroSpect Digital Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IntroSpect Digital Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              atai Life Sciences and Introspect Digital Therapeutics to Test Novel Digital Therapeutic Approach in Patients Receiving Ketamine

              Details:

              Integration of Introspect’s digital therapeutic with R-ketamine therapy for patients with treatment resistant depression.

              Lead Product(s): R-Ketamine

              Therapeutic Area: Psychiatry/Psychology Product Name: PCN-101

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: ATAI Life Sciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration September 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY